<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675012</url>
  </required_header>
  <id_info>
    <org_study_id>NGR005</org_study_id>
    <secondary_id>2007-003668-24</secondary_id>
    <nct_id>NCT00675012</nct_id>
  </id_info>
  <brief_title>NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGC Biologics S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGC Biologics S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to document the safety of NGR-hTNF administered at low and&#xD;
      high doses in combination with a standard oxaliplatin based regimen in patients with&#xD;
      metastatic colorectal cancer not amenable to any clinical improvement by current standard&#xD;
      treatments&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, open-label, non-randomized study that will be conducted in two sequential cohorts&#xD;
      of patients. Patients with metastatic colorectal cancer not amenable to any clinical&#xD;
      improvement by current standard treatments are planned to be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.</measure>
    <time_frame>during the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII</measure>
    <time_frame>before during and following the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NGR-hTNF</intervention_name>
    <description>iv 0.8 or 45 mcg/sqm q3W</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>orally 825 mg/sqm 2qDx14</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years with metastatic colorectal cancer (CRC) treated with no more than&#xD;
             three standard systemic regimens (including biologic agents) for metastatic disease&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  ECOG Performance status 0-1&#xD;
&#xD;
          -  Adequate baseline bone marrow, hepatic and renal function, defined as follows:&#xD;
&#xD;
               -  Neutrophils &gt;1.5 x 10^9/L and platelets &gt; 100 x 10^9/L&#xD;
&#xD;
               -  Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  AST and/or ALT &lt;2.5 x ULN in absence of liver metastasis&#xD;
&#xD;
               -  AST and/or ALT &lt;5 x ULN in presence of liver metastasis&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 x ULN&#xD;
&#xD;
               -  Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min&#xD;
&#xD;
          -  Patients may have had prior therapy providing the following conditions are met:&#xD;
&#xD;
               -  Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out&#xD;
                  period of 28 days before start treatment&#xD;
&#xD;
               -  Surgery: wash-out period of 14 days before start treatment&#xD;
&#xD;
          -  Patients must give written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent anticancer therapy&#xD;
&#xD;
          -  Patients must not receive any other investigational agents while on study&#xD;
&#xD;
          -  Patients with myocardial infarction within the last six (6) months, unstable angina,&#xD;
             New York Heart Association (NYHA) grade II or greater congestive heart failure, or&#xD;
             serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Prolonged QTc interval (congenital or acquired)&#xD;
&#xD;
          -  Patient with significant peripheral vascular disease&#xD;
&#xD;
          -  Clinical signs of CNS involvement&#xD;
&#xD;
          -  Patients with active or uncontrolled systemic disease/infections or with serious&#xD;
             illness or medical conditions, which is incompatible with the protocol&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy ≥ grade 1 according the NCI CTCAE v.3.0.&#xD;
&#xD;
          -  Known hypersensitivity/allergic reaction or contraindications to human albumin&#xD;
             preparations or to any of the excipients&#xD;
&#xD;
          -  Known hypersensitivity/allergic reaction or contraindications to platinum compounds or&#xD;
             fluoropyrimidines&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Patients - both males and females - with reproductive potential (i.e. menopausal for&#xD;
             less than 1-year and not surgically sterilized) must practice effective contraceptive&#xD;
             measures throughout the study.&#xD;
&#xD;
          -  Women of childbearing potential must provide a negative pregnancy test (serum or&#xD;
             urine) within 14 days prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Sobrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria San Martino Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol. 2011 Apr;22(4):973-978. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20.</citation>
    <PMID>20855468</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NGR-hTNF</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

